Treatment options for

metastatic urothelial carcinoma:

eLearning activities

Activity 2: Immunotherapy in advanced urothelial cancer: second-line and beyond

Part 2: Subsequent-line immunotherapy options for patients with mUC


Post-assessment question 1 of 1
Erdafitinib has been shown to have significant second-line activity in…

Once you have submitted your answer you will be taken directly to the activity Evaluation form. Please take a minute to complete it, your feedback helps us to deliver the best learning experience.